Prevalence of Autoimmune Thyroid Markers in Euthyroid Women With Polycystic Ovary syndrome

Assessment of Autoimmune Thyroid Markers in Euthyroid Egyptian Patients with Polycystic Ovary Syndrome

¹Ahmed Mohamed Bahaa El-din, ¹Alyaa Ahmed El-Sherbeny, ¹Emad Abd El-mohsen Abd El-hadi, ¹Hesham Abouellail and ²Manal Mohsen

¹Internal Medicine, Faculty of Medicine, Ain Shams University, Egypt


²Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt

OBJECTIVES:

to compare the prevalence, levels of thyroid auto-antibodies in a group of Egyptian women with PCOS and a control group in reproductive age to determine whether women with PCOS have a greater risk of thyroid autoimmune diseases, thyroid dysfunction or not.

METHODS:

This study was conducted on 45 euthyroid women with PCOS and 18 healthy women as a control in the Outpatient Clinics of Endocrinology, Ain Shams University hospital. PCOS was defined by the revised 2003 Rotterdam criteria. Thyroid function was evaluated by measurement of TSH and FT4 levels, antithyroid peroxidase and antithyroglobulin antibodies (anti-TPO and anti-TG, respectively) as markers for thyroid autoimmunity.All parameters were measured using electrochemiluminescence immunoassay.



CONCLUSIONS

This study shows that PCOS was associated with presence of positive thyroid auto-antibodies in the sera of Egyptian patients; so that, these patients could be at increased risk of thyroid disorders (and fetal loss?). Thyroid autoimmunity markers should be requested in patients with PCOS who decide to get pregnant even when there is no evidence of overt thyroid dysfunction

RESULTS:

Women with PCOS had significantly higher levels of anti-TPO in comparison to controls (27 ± 10 and 21 ± 10 IU/mL, respectively; *p*< 0.05) and no significant difference was found in serum levels of anti-TG, TSH, or FT4 between the two groups. Patients with PCOS had a non significant higher prevalence of positive results for anti-TG and/or anti-TPO in comparison to controls (40% and 22.2%, respectively; *p* > 0.05), anti-TPO alone (28.9% and 16.7%, respectively; *p* > 0.05) and anti-TG alone (22.2% and 11.1%, respectively; *p* > 0.05). No significant associations were found between the assayed antibodies and thyroid hormones.

REFERENCES:

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *FertilSteril*. Feb 2009;91(2):456-88.

Barber TM, Franks S, Genetic basis of polycystic ovary syndrome. Expert Rev EndocrinolMetab. 2010;5(4):549-61

Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. *ClinEndocrinol (Oxf)*. Aug 2006;65(2):137-45.

Miscarriage.Expert Rev EndocrinolMetab. 2008;3(2):127-136.

Gerasimos E. Krassas, PetrosPerros, AthinaKapraraThyroid Autoimmunity, Infertility and

Rotterdam EAPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.

Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary:

international consensus definitions. Hum Reprod Update. 2003;9(6):505–14. Petrikova J, Lazurova I, Yehuda S. Polycystic ovary syndrome and autoimmunity. Eur J Intern

Med.2010;21(5):369–71. doi: 10.1016/j.ejim.2010.06.008.

Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. FertilSteril. 2011;95(3):1048–58 e1-2. doi: 10.1016/j.fertnstert.2010.11.036.

Hefler-Frischmuth K, Walch K, Huebl W, Baumuehlner K, Tempfer C, Hefler L. Serologic markers of autoimmunity in women with polycystic ovary syndrome. FertilSteril. 2010;93(7):2291–4. doi: 10.1016/j.fertnstert.2009.01.056.

Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gartner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150(3):363–9. Sinha U, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK. Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. Indian J EndocrinolMetab. 2013;17(2):304–9. doi: 10.4103/2230-8210.109714. Ozdemir D, Cuhaci N, Balkan F, Usluogullari A, Ersoy R, Cakir B. Prevalence of thyroid pathologies in patients with polycystic ovary syndrome. EndocrAbstr. 2011;26:92.

pathologies in patients with polycystic ovary syndrome. EndocrAbstr. 2011;26:92.

Raghad Al-Saab and Shaden Haddad. Detection of thyroid autoimmunity markers in euthyroid women withpolycystic ovary syndrome: A case-control study from Syria. Int J Endocrinol Metab. Jul 2014; 12(3): e17954.doi: 10.5812/ijem.17954.

Kachuei M, Jafari F, Kachuei A, Keshteli AH. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2012;285(3):853–6. doi: 10.1007/s00404-011-2040-5.

Du D, Li X. The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. Int J ClinExp Med. 2013 Oct 25; 6(10):880-9.

Ott J, Aust S, Kurz C, Nouri K, Wirth S, Huber JC, Mayerhofer K. Elevated antithyroid peroxidase antibodies indicating Hashimoto's thyroiditis are associated with the treatment response in infertile women with polycystic ovary syndrome. FertilSteril. 2010 Dec;94(7):2895-7.





DOI: 10.3252/pso.eu.17ece.2015



